Health risks outweigh benefits for combined estrogen plus progestin. Clinical trial stopped early in major study.
D000368:Aged; D001943:Breast Neoplasms / Q000453:epidemiology; D015179:Colorectal Neoplasms / Q000517:prevention & control; D003327:Coronary Disease / Q000453:epidemiology / Q000517:prevention & control; D004338:Drug Combinations; D015914:Estrogen Replacement Therapy; D004966:Estrogens, Conjugated (USP) / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006620:Hip Fractures / Q000517:prevention & control; D020249:Hormone Replacement Therapy / Q000009:adverse effects; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage; D008875:Middle Aged; D010919:Placebos; D017698:Postmenopause; D045167:Progesterone Congeners / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology; D013997:Time Factors; D020246:Venous Thrombosis / Q000453:epidemiology
D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); D010919:Placebos; D045167:Progesterone Congeners; D017258:Medroxyprogesterone Acetate